Baseline characteristics, prior bisphosphonate (BPH) therapy (Rx), and clinical parameters of patients in LOTUZ, a prospective pharmacoepidemiological study of long-term zoledronic acid (ZOL) treatment (≥2 years) in patients (pts) with solid and hematologic malignancies

20597 Background: There is a trend towards long-term Rx with ZOL. The LOTUZ study is among the first to examine ZOL Rx treatment patterns, effectiveness, and safety beyond 2 years. Reported are bas...